Related Experiment Video

Updated: Feb 14, 2026

Heterotypic Three-dimensional In Vitro Modeling of Stromal-Epithelial Interactions During Ovarian Cancer Initiation and Progression
12:42

Heterotypic Three-dimensional In Vitro Modeling of Stromal-Epithelial Interactions During Ovarian Cancer Initiation and Progression

Published on: August 28, 2012

15.7K

Antisense lncRNA As-SLC7A11 suppresses epithelial ovarian cancer progression mainly by targeting SLC7A11

Jinjin Yuan, Zongwen Liu, Rui Song

    Die Pharmazie
    |February 15, 2018
    PubMed

    Insights

    Antisense RNA (As-SLC7A11) is reduced in epithelial ovarian cancer (EOC), promoting cancer cell migration. Restoring As-SLC7A11 levels induces apoptosis, highlighting its tumor suppressor role in EOC treatment.

    Area of Science:

    • Oncology
    • Molecular Biology
    • Genetics

    Background:

    • Antisense long non-coding RNAs (lncRNAs) are implicated in cancer progression.
    • Understanding antisense lncRNAs is crucial for epithelial ovarian cancer (EOC) treatment strategies.

    Purpose of the Study:

    • To investigate the role and mechanism of antisense RNA SLC7A11 (As-SLC7A11) in epithelial ovarian cancer (EOC).
    • To determine the potential of As-SLC7A11 as a therapeutic target in EOC.

    Main Methods:

    • Quantitative analysis of As-SLC7A11 expression in EOC tissues and cell lines.
    • In vitro studies involving silencing and overexpression of As-SLC7A11.
    • Assessment of cell migration and apoptosis.
    • Correlation analysis between As-SLC7A11 and SLC7A11 expression.

    Main Results:

    • As-SLC7A11 levels were significantly reduced in EOC tissues and cell lines compared to normal controls.
    • Silencing As-SLC7A11 enhanced ovarian cancer cell migration.
    • Overexpression of As-SLC7A11 induced ovarian cancer cell apoptosis.
    • As-SLC7A11 overexpression suppressed SLC7A11 expression, indicating a negative correlation.

    Conclusions:

    • As-SLC7A11 functions as a tumor suppressor in ovarian cancer.
    • Reduced As-SLC7A11 levels promote EOC cell migration by suppressing SLC7A11 expression.
    • As-SLC7A11 represents a potential therapeutic target for EOC treatment.

    More Related Videos

    An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses10:35

    An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses

    Published on: November 28, 2010

    18.9K
    Method for Obtaining Primary Ovarian Cancer Cells From Solid Specimens05:58

    Method for Obtaining Primary Ovarian Cancer Cells From Solid Specimens

    Published on: February 4, 2014

    14.2K

    Related Concept Videos

    lncRNA - Long Non-coding RNAs02:39

    lncRNA - Long Non-coding RNAs

    In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
    10.0K
    lncRNA - Long Non-coding RNAs02:39

    lncRNA - Long Non-coding RNAs

    3.7K
    mTOR Signaling and Cancer Progression03:03

    mTOR Signaling and Cancer Progression

    The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
    The mTOR pathway or the...
    4.9K
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against...
    9.0K
    Tumor Progression02:07

    Tumor Progression

    Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
    Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
    7.5K
    Ovarian Cycle01:27

    Ovarian Cycle

    The menstrual cycle includes a critical component known as the ovarian cycle, which undergoes two main phases each month—the follicular phase and the luteal phase. The follicular phase is variable and averaging around 14 days. Ovulation, triggered by a surge in luteinizing hormone (LH), marks the transition between the two phases. The second phase, the luteal phase, is relatively consistent, lasting approximately 14 days, and is marked by the activity of the corpus luteum. While a cycle...
    4.3K